- Home
- EVV vs RCUS Comparison
EVV vs RCUS Comparison
Compare EVV & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- RCUS
- Stock Information
- Founded
- EVV 2003
- RCUS 2015
- Country
- EVV United States
- RCUS United States
- Employees
- EVV N/A
- RCUS N/A
- Industry
- EVV Finance/Investors Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- RCUS Health Care
- Exchange
- EVV Nasdaq
- RCUS Nasdaq
- Market Cap
- EVV 1.2B
- RCUS 1.4B
- IPO Year
- EVV N/A
- RCUS 2018
- Fundamental
- Price
- EVV $9.87
- RCUS $13.92
- Analyst Decision
- EVV
- RCUS Buy
- Analyst Count
- EVV 0
- RCUS 12
- Target Price
- EVV N/A
- RCUS $34.50
- AVG Volume (30 Days)
- EVV 323.7K
- RCUS 636.5K
- Earning Date
- EVV 01-01-0001
- RCUS 02-19-2025
- Dividend Yield
- EVV 9.66%
- RCUS N/A
- EPS Growth
- EVV N/A
- RCUS N/A
- EPS
- EVV N/A
- RCUS N/A
- Revenue
- EVV N/A
- RCUS $263,000,000.00
- Revenue This Year
- EVV N/A
- RCUS $127.65
- Revenue Next Year
- EVV N/A
- RCUS N/A
- P/E Ratio
- EVV N/A
- RCUS N/A
- Revenue Growth
- EVV N/A
- RCUS 119.17
- 52 Week Low
- EVV $8.52
- RCUS $13.51
- 52 Week High
- EVV $10.07
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- EVV 40.68
- RCUS 33.83
- Support Level
- EVV $9.74
- RCUS $14.86
- Resistance Level
- EVV $10.07
- RCUS $15.62
- Average True Range (ATR)
- EVV 0.09
- RCUS 0.63
- MACD
- EVV 0.01
- RCUS -0.14
- Stochastic Oscillator
- EVV 39.39
- RCUS 15.95
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure among others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.